Drug intelligence / Profile preview

dolichovespula maculata venom protein

Development stage
Unknown
Lead developer
ALK Abelló
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intradermal, Percutaneous
01

Overview

Dolichovespula maculata venom protein is a biologic extract derived from the venom of the bald-faced hornet (Dolichovespula maculata). It contains a complex mixture of biologically active compounds including enzymes, peptides, and proteins[2]. The primary clinical use is in allergy testing and diagnosis of hypersensitivity to vespid stings. The major allergenic component is antigen 5 (Dol m 5), a cysteine-rich 204-residue protein that serves as an important T-cell epitope in allergic responses[5]. Its mechanism involves eliciting an immune response in sensitized individuals for diagnostic purposes. This product is classified as an allergenic extract and used primarily for identifying patients at risk for severe allergic reactions to vespid stings[1][4].

Other names
bald-faced hornet venom proteinwhite faced hornet venom proteinwhite-faced hornet venom proteinallergen Dol m V-Bantigen 5 form 3antigen5 form 3antigen-5 form 3cysteine-rich venom protein
02

Targets

TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on dolichovespula maculata venom protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dolichovespula maculata venom protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call